NCT00192647View on ClinicalTrials.gov

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

896

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hepatitis C, Chronic
Interventions
DRUG

PEG-IFN alfa-2a

PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.

DRUG

Ribavirin

Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.

Trial Locations (51)

100

Auckland

1640

Buenos Aires

1871

Liverpool

2000

Rosario

2010

Darlinghurst

Sydney

2050

Sydney

2139

Sydney

2145

Sydney

2170

Liverpool

2200

Bankstown

2228

Miranda

2310

New Lambton Heights

2480

Lismore

2500

Wollongong

2606

Woden

3011

Melbourne

3052

Parkville

3065

Fitzroy

3084

Melbourne

3128

Box Hill

3181

Melbourne

3186

Melbourne

3199

Victoria

3220

Geelong

4029

Brisbane

4102

Woolloongabba

4120

Greenslopes

4558

Cottontree

5000

Adelaide

5042

Adelaide

6001

Perth

6009

Nedlands

6160

Fremantle

8011

Riccarton, Christchurch

10400

Bangkok

10700

Bangkok

44280

Guadalajara

44650

Guadalajara

50202

Chiang Mai

64460

Monterrey

C1282AFE

Buenos Aires

B1902AVF

La Plata

Unknown

Douglas

Kingswood

Hamilton

T2N 4N1

Calgary

T5H 4B9

Edmonton

V5Z 1M9

Vancouver

L5M 2V8

Mississauga

H3T 1E2

Montreal

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00192647 - A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection | Biotech Hunter | Biotech Hunter